GYKI 52466, Selective non-competitive AMPA antagonist

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The Glutamate Receptor 1 (AMPA subtype) also known as GluA1 or GRIA1 is an ionotropic receptor involved in fast excitatory neurotransmission in the brain. It is one of the major players in mediating synaptic transmission at glutamatergic synapses. This receptor forms a tetrameric complex and has an approximate mass of 100 kDa per subunit. It is widely expressed in regions such as the hippocampus cerebral cortex and cerebellum where it plays an important role in synaptic plasticity and modulation of synaptic strength.

Biological function summary

Glutamate Receptor 1 operates as part of the AMPA receptor complex influencing synaptic signaling and plasticity. This receptor facilitates rapid synaptic transmission by mediating sodium influx upon binding with glutamate. The GluA1 subunit is often partnered with other AMPA subunits like GluA2 GluA3 or GluA4 to form functional channels which contribute to the strength and stability of synaptic connections important for learning and memory.

Pathways

This receptor plays a significant role in synaptic plasticity and the long-term potentiation (LTP) pathway which are essential for learning and memory processes. It associates with the NMDA receptor-mediated pathways to initiate LTP as the NMDA receptor's activation leads to an increased insertion of AMPA receptors at synapses. Furthermore the receptor is involved with the dopamine D2 receptor in modulating synaptic transmission and plasticity impacting dopaminergic signaling pathways.

Glutamate Receptor 1 is linked to neurological conditions such as epilepsy and schizophrenia. Altered expression or dysfunction of AMPA receptors can lead to an imbalance in excitatory synaptic transmission contributing to these conditions. The receptor’s interaction with the dopamine D2 receptor underlies its involvement in psychotic disorders as dopaminergic signaling dysregulation is a hallmark of schizophrenia. Modulation by AMPA antagonists like GYKI 52466 provides therapeutic avenues for managing these disorders.